Department of Urology, School of Medicine, Istanbul Medipol University, Çamlık Mah, Piri Reis Cad, Papatya Sitesi No 48, Pendik, Istanbul, 34890, Turkey.
Int Urol Nephrol. 2019 Sep;51(9):1491-1499. doi: 10.1007/s11255-019-02211-4. Epub 2019 Jun 22.
We aimed to investigate the efficacy and safety of tadalafil, aspirin, and tadalafil + aspirin combination therapy in vascular erectile dysfunction (VED).
A total of 336 patients were randomly divided into four groups (group 1, aspirin 100 mg/day, 126 patients; group 2, tadalafil 5 mg/day, 72 patients; group 3, tadalafil 5 mg + aspirin 100 mg, 72 patients; group 4, placebo, 66 patients). In all groups, the changes from baseline to end point in erectile function scores on the International Index of Erectile Function (IIEF-EF) and the number of patients who answered "yes" to questions 2 and 3 of the sexual encounter profile(SEP) were compared statistically.
The changes in IIEF-EF scores after treatment were 7.2 ± 4.4, 7.3 ± 4.3, 7.5 ± 4.4, and 2.0 ± 4.6 for group 1 (p < 0.0001), group 2 (p < 0.0001), group 3 (p < 0.0001), and group 4 (p = 0.0204), respectively. The change in SEP-2 ratios after treatment were 36.6%, 36.9%, 41.7%, and 9.4% for group 1 (p < 0.0001), group 2 (p < 0.0001), group 3 (p < 0.0001), and group 4 (p = 0.2925), respectively. The change in SEP-3 ratios after treatment was 46.6%, 49.2%, 53.7%, and 12.5% for group 1 (p < 0.0001), group 2 (p < 0.0001), group 3 (p < 0.0001), and group 4 (p = 0.1456), respectively. In group 2, both the number of patients who reported side effects (p < 0.0001) and stopped using the drug due to side effects (p < 0.05) were significantly higher than the control and others groups.
Successful results were obtained by tadalafil and aspirin monotherapy and tadalafil + aspirin combination therapy in patients with VED. However, the least side effect was observed in the tadalafil + aspirin group. Aspirin can be used alone in the treatment of patients with VED, or combined with tadalafil to reduce side effects and increase success.
我们旨在研究他达拉非、阿司匹林和他达拉非+阿司匹林联合治疗血管性勃起功能障碍（VED）的疗效和安全性。
共有 336 名患者被随机分为四组（第 1 组，阿司匹林 100mg/天，126 例；第 2 组，他达拉非 5mg/天，72 例；第 3 组，他达拉非 5mg+阿司匹林 100mg，72 例；第 4 组，安慰剂，66 例）。所有组均比较基线至终点时国际勃起功能指数（IIEF-EF）中勃起功能评分的变化，以及性遭遇剖面图（SEP）第 2 和第 3 题回答“是”的患者数量。
治疗后 IIEF-EF 评分的变化分别为组 1（p<0.0001）、组 2（p<0.0001）、组 3（p<0.0001）和组 4（p=0.0204）的 7.2±4.4、7.3±4.3、7.5±4.4 和 2.0±4.6；治疗后 SEP-2 比值的变化分别为组 1（p<0.0001）、组 2（p<0.0001）、组 3（p<0.0001）和组 4（p=0.2925）的 36.6%、36.9%、41.7%和 9.4%；治疗后 SEP-3 比值的变化分别为组 1（p<0.0001）、组 2（p<0.0001）、组 3（p<0.0001）和组 4（p=0.1456）的 46.6%、49.2%、53.7%和 12.5%。在第 2 组中，报告副作用的患者数量（p<0.0001）和因副作用而停药的患者数量（p<0.05）均明显高于对照组和其他组。
他达拉非和阿司匹林单药治疗以及他达拉非+阿司匹林联合治疗 VED 患者均取得了成功结果。然而，在他达拉非+阿司匹林组观察到的副作用最少。阿司匹林可单独用于治疗 VED 患者，或与他达拉非联合使用以降低副作用并提高成功率。
